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Abstract 
 
The prevalence of  Non-Hodgkin lymphomas (NHL)  survivors is increasingbecause of the advances in 
multimodality treatment approaches which later has become the reason for various late side-effects especially 
secondary malignant neoplasms. Among these secondary malignancies gynaecological cancers are rarely found in 
literature . Here we report one previously treated case of NHL in a middle aged female who later developed 
carcinoma cervix as a metachronus second primary malignancy. 
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Introduction 
Non-Hodgkin lymphomas (NHL) are a heterogeneous 
group of malignancies of the lymphoid system 
characterized by an abnormal clonal proliferation of B 
cells, T cells, or both. According to GLOBOCAN 2018 
data NHLs are 11th most common cancers in India 
with incidence of 28110 cases (2.68% of total).In India, 
carcinoma of cervix is the second most common cancer 
in females after breast cancer and is the most common 
gynaecological malignancy.  
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According to GLOBOCAN 2018 data incidence is 
96922 cases (9.23% of total and 16.5% of female 
cancers)[1].Survivors of NHL patients may rarely had 
a chance of developing second malignancies especially  
in gynaecologicalregion. 
 
Case report 
A 54 year old female with no comorbidities presented 
on 11/11/2010 with complaint of swelling in both sides 
of neck since 2 months. No other complaints like 
difficulty in swallowing, pain, fever . Biopsy done 
outside suggested that secondary carcinomatous 
depositis. After that, patient presented to Medical 
Oncology outpatient department in Sri Venkateswara 
Institute Of Medical Sciences (SVIMS).Endoscopy 
was normal, Indirect laryngoscopy was normal and 
direct nasal examination also normal. 
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Review biopsy(RB196/10) suggestive of Non hodgkins 
lymphoma- diffuse small and large cleared cell type- 
intermediate grade. On Immunohistochemical 
examination (IRB 196/10): neoplastic cells were 
CD20: positive, UCHL- I : T cells shows moderate to 
intense positivity, Kp-I: moderate to intense positivity, 
BCL2: moderate to intense positivity ,CD10: Negative 
. Suggested the Impression of  Diffuse large B cell 
NHL –High grade.Trephine biopsy: 
B5417/10(17.12.10: Hypercellular micro normoblastic 
bonemarrow with neoplastic infiltration.BM 
Examination BM1184/10( 21.12.10): Hypercellular 
micro normoblastic bonemarrow with neoplastic 
infiltration. Chest X ray :  normal study.Haemogram 
was within normal limits.EHCO: LVEF 59%, no 
RWMA, Normal LV systolic function. Patient treated 
with 6 cycles of CHOP( Cyclophosphamide, 
Doxorubicin, Vincristine, Prednisolone) regimen, last 
cycle on 11/5/2011. After that patient daefaulted for 4 
years  due to her personal reasons. Again patient was 
presented after 6 years on 25/5/2017 to Radiation 
Oncology outpatient department with complaints of 
lower abdominal pain and bleeding per vagina . 
Physical examination revealed her blood pressure 
110/82 mm of Hg , pulse rate 90/min , respiratory rate 
14/min. Gynaecological examination suggestive of 
ulceroproliferative growth of size 4×3 cm arising from 
cervix. All fornices and upper half of anterior vaginal 
wall involved and left parametrium medially involved. 
No involvement of inguinal and supraclavicular 
lymphnodes. Biopsy done from the growth and 
diagnosed as infiltrating moderately differentiated 
squamous cell carcinoma (Fig.1 & Fig.2). Patient 
diagnosed as carcinoma cervix stage IIB and metastatic 
workup done. 
 
 
Fig.1: Photomicrograph showing moderately differentiated malignancy (Haematoxylin and eosin ×40) 
 
Fig.2: Photomicrograph showing infiltrating moderately differentiated squamous cell malignancy 
(Haematoxylin and eosin ×100) 
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Routine blood investigations such as haemogram, renal 
function test, liver function test are normal. 
patient is diagnosed positive for Hepatitis B antigen 
HBsAg by ELISA test and human papilloma virus 
DNA detected from cervical growth by nested 
multiplex polymerase chain reaction (NM-PCR).  
FDG PET CT done in view of previous history of non 
hodgkins lymphoma suggestive of metabolically active 
soft tissue density lesion in cervix with bilateral 
parametrial fat stranding noted with pyometra. 
Metabolically active left external iliac (1.6×1.2 cm) 
and aortocaval (1×0.7 cm) lymphnodes present.No 
evidence of distant metastasis (Fig.3). 
Patientwas  admitted for radiotherapy and treated with 
external beam radiotherapy of dose 50.4  Gy (grey) in 
28 # (fractions) @ 1.8 Gy per fraction and with three 
fractions of  intracavitary brachytherapy @ 7 Gy per 
fraction, completed treatment on 01.10.2017. Now she 
is on followup, feeling well without any recurrence or 
progression, last followup was on 22.09.2018. 
 
 
 
Fig.3: Maximum intensity projection image(A). CT axial image(B) and fused PET-CT image(C) 
Showing intense FDG uptake in cervix. CT axial image(D) and fused PET-CT image(E) showing intense FDG 
uptake in left external iliac lymphnode. 
 
Discussion 
NHL is a heterogeneous group of malignancies 
characterized by an abnormal clonal proliferation of T-
cells, B-cells or both. The majority of the adult NHLs 
are of B-cell origin[2]. NHLs range from indolent 
malignancies (low-grade histologies) to rapidly 
growing and highly aggressive tumors (high-grade 
histologies). The overall median age at presentation is 
42 years  and the incidence increases with advancing 
age. NHL usually involves the lymph nodes but can 
involve extranodal sites and can occur in the stomach, 
skin, lung, salivary glands and rarely in the mouth[3]. 
 The main symptom of NHL is swelling of lymph 
nodes in the neck, under the arms or in the groin. Other 
symptoms can include fever, night sweats, fatigue, 
abdominal pain and unexplained weight loss. 
Lymphomas usually are painless; lymph nodes may get 
larger slowly over a long time before the patient 
notices. Fever commonly associated with lymphoma 
may appear and disappear for several weeks[4].  
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Chemotherapy with or without radiation therapy has 
been the mainstay of non-Hodgkin’s lymphoma (NHL) 
treatment. In the past few years, evolving therapies 
have led to improved long-term survival for some 
histological subtypes, and the introduction of 
monoclonal antibody treatments has further improved 
the prognosis of indolent[5-7] and aggressive [8-12] B-
cell NHL. High-dose chemotherapy followed by 
autologous stem-cell transplantation (ASCT) and 
allogeneic bone marrow transplantation has emerged as 
another promising approach for the treatment of 
relapsed lymphoma or as part of plannedtreatment of 
neoplasm with a poor prognosis [13-16]. As a result of 
these advances, the prevalence of NHL survivors 
isincreased and late side-effects of treatment such as 
secondary malignant neoplasms (SMNs), ischemic 
heart disease, anthracycline-related cardiotoxicity, and 
radiation or bleomycin-induced pulmonary 
toxicity[17]. 
Results from a metaanalysis including 23 studies of 
NHL  patients showed that there is a higher risk of 
developing secondary malignancies in NHL survivors 
compared to general population, the Pooled relative 
risk for overall and for solid tumors were 1.88 and 
1.32, respectively[18]. Among solid tumors lung 
cancers are most common followed by  skin, head and 
neck cancers[19], hence the development of carcinoma 
cervix is relatively rare compared to other 
malignancies. To the best of our knowledge this is a 
one of the rare case reports of metachronus carcinoma 
cervix in treated case of Non Hodgkins Lymphoma. 
 
Conclusion 
As gynaecological malignancies such as carcinoma 
cervix is rarely reported as metachronus second 
primary malignancy in a previously treated case of 
NHL which can be attributed to previous treatment or a 
sporadic event, the possibility of its occurrence should 
not be underestimated, there by the timely screening 
and early diagnosis of carcinoma cervix as second 
neoplasms can improve the survival and quality of life 
in NHL survivors. 
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